Clinical Research Directory

Inclusion Criteria: * Undergoing one of the following orthopedic shoulder surgeries: * Total shoulder arthroplasty * Reverse total shoulder arthroplasty * Shoulder hemiarthroplasty * Rotator cuff repair * Receiving standard anesthesia during surgery * If a subject is of reproductive potential, they must be on effective contraception one month prior, during treatment, and one month following treatment. Exclusion Criteria: * Not above the age of 18 years old * History of revision shoulder arthroplasty * History of liver disease or impairment * Are currently taking valproate or clobazam * Are currently taking a moderate/strong CYP3A4 or CYP2C19 inhibitor * Are currently taking a strong CYP3A4 or CYP2C19 inducer * Are currently taking narcotics * History of substance/alcohol abuse * Those currently or previously under the care of a pain management specialist * History of marijuana/cannabidiol (not including topical) regular use within the past 6 months * Allergy related to cannabidiol * Allergy related to sesame seeds * Pregnancy (As part of standard of care, all female participants will be administered a urine pregnancy test prior to surgery. A negative test result is required to participate in the study.) * If you are taking any medications with known risks for suicidal behavior and ideation * If you have a diagnosed psychiatric or sleeping disorder * If you are actively breastfeeding * Patients currently taking central nervous system (CNS) depressants * Patients currently taking other drugs with known hepatotoxicity * Vulnerable populations. Patients taking concomitant medications which are substrate of uridine 5'-diphospho-glucuronosyltransferase 1-9 (UGT1A9), uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7), CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and P-gp will be monitored for potential adverse events based on the Epidiolex® label for the concomitant medication being used.